COSMOS Pharmaceutical Corporation (3349.T)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Forecast and Price Target with Analyst Ratings, Revenue Estimates, and complete financial and advanced discounted cashflow forecasts for up to 10 years.

Trending:

COSMOS Pharmaceutical Corporation (3349.T) Stock Forecast & Price Prediction | Analyst Ratings

Revenue

1.54T

Higher than competitor

Better than 3088.T's revenue of 1.01T.

Revenue Growth Rate

8.74%

Higher than competitor

Better than 3088.T's revenue growth rate of -0.94%.

EBITDA

94.99B

Higher than competitor

Better than 3088.T's ebitda of 88.74B.

EBITDA Margin

6.18%

Lower than competitor

Worse than 3088.T's ebitda margin of 8.76%.

EBIT

63.44B

Lower than competitor

Worse than 3088.T's ebit of 68.33B.

EBIT Margin

4.13%

Lower than competitor

Worse than 3088.T's ebit margin of 6.75%.

Depreciation

31.55B

Higher than competitor

Worse than 3088.T's depreciation of 20.42B.

Total Cash

89.61B

Lower than competitor

Worse than 3088.T's total cash of 99.58B.

Cash as Percentage of Revenue

5.83%

Lower than competitor

Worse than 3088.T's cash as percentage of revenue of 9.83%.

Receivables

17.70B

Lower than competitor

Better than 3088.T's receivables of 87.31B.

Receivables as Percentage of Revenue

1.15%

Lower than competitor

Better than 3088.T's receivables as percentage of revenue of 8.62%.

Inventories

136.97B

Lower than competitor

Better than 3088.T's inventories of 154.06B.

Inventories as Percentage of Revenue

8.91%

Lower than competitor

Better than 3088.T's inventories as percentage of revenue of 15.22%.

Accounts Payable

284.20B

Higher than competitor

Worse than 3088.T's accounts payable of 109.30B.

Payables as Percentage of Revenue

18.48%

Higher than competitor

Worse than 3088.T's payables as percentage of revenue of 10.79%.

Capital Expenditure

-80.07B

Lower than competitor

Better than 3088.T's capital expenditure of -13.52B.

CapEx as Percentage of Revenue

-5.21%

Lower than competitor

Better than 3088.T's capex as percentage of revenue of -1.34%.

Weighted Average Cost of Capital (WACC)

4.64%

Lower than competitor

Better than 3088.T's weighted average cost of capital (wacc) of 4.93%.

Cost of Equity

4.78%

Lower than competitor

Better than 3088.T's cost of equity of 4.93%.

Cost of Debt

3.69%

Lower than competitor

Better than 3088.T's cost of debt of 3.99%.

Beta

0.23

Higher than competitor

Worse than 3088.T's beta of 0.17.

Diluted Shares Outstanding

79.26M

Lower than competitor

Better than 3088.T's diluted shares outstanding of 408.61M.

Total Debt

49.96B

Higher than competitor

Worse than 3088.T's total debt of 2.21B.

Total Equity

694.13B

Lower than competitor

Worse than 3088.T's total equity of 1.17T.

Total Capital

744.09B

Lower than competitor

Worse than 3088.T's total capital of 1.17T.

Debt Weighting

6.71%

Higher than competitor

Worse than 3088.T's debt weighting of 0.19%.

Equity Weighting

93.29%

Lower than competitor

Worse than 3088.T's equity weighting of 99.81%.

EBIAT

45.51B

Higher than competitor

Better than 3088.T's ebiat of 44.76B.

Unlevered Free Cash Flow

7.40B

Lower than competitor

Worse than 3088.T's unlevered free cash flow of 52.92B.

Long-Term Growth Rate

2.00%

Lower than competitor

Worse than 3088.T's long-term growth rate of 3.00%.

Terminal Value

286.18B

Lower than competitor

Worse than 3088.T's terminal value of 2.82T.

Enterprise Value

267.58B

Lower than competitor

Worse than 3088.T's enterprise value of 2.45T.

Net Debt

-7.08B

Higher than competitor

Worse than 3088.T's net debt of -109.55B.

Equity Value

274.66B

Lower than competitor

Worse than 3088.T's equity value of 2.56T.

Equity Value Per Share

3465.48

Lower than competitor

Worse than 3088.T's equity value per share of 6262.49.

Select Metric for Chart